Nathan Fletcher

Nathan Fletcher is a proficient commercial analyst with extensive experience in the pharmaceutical and healthcare sectors, currently employed at AAH Pharmaceuticals since June 2023. Prior experience includes roles at Orbit Group and McKesson UK, where Nathan contributed as a commercial analyst and insights executive, respectively. Additional experience encompasses positions at PET-Xi Training, Health Unlimited, and Horizon Platforms Ltd, where Nathan held roles in project management, training, and sales analysis. Nathan began the professional journey as a graduate case analyst at Capita, focusing on the investigation of PPI mis-selling for Lloyds Banking Group. Nathan holds a Bachelor’s Degree in Cell/Cellular and Molecular Biology from Newcastle University, earned between 2010 and 2013.